{"created":"2024-11-22T06:50:06.849208+00:00","id":2008297,"links":{},"metadata":{"_buckets":{"deposit":"4d588377-7a7f-490f-a827-b7e051c1355f"},"_deposit":{"created_by":7,"id":"2008297","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2008297"},"status":"published"},"_oai":{"id":"oai:tokushima-u.repo.nii.ac.jp:02008297","sets":["1713829974766:1713854682253:1716422247219:1716422749171","1713853213384:1713853295607"]},"author_link":["852","518","781","710","359","349","175","1572","287"],"item_10001_alternative_title_1":{"attribute_name":"タイトル別表記","attribute_value_mlt":[{"subitem_alternative_title":"Correlation between effects of checkpoint inhibitors and immune-related adverse events in patients with gastric cancer","subitem_alternative_title_language":"en"},{"subitem_alternative_title":"胃癌における免疫チェックポイント阻害薬の副作用と効果の関連性","subitem_alternative_title_language":"ja"}]},"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-08-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3-4","bibliographicPageEnd":"178","bibliographicPageStart":"173","bibliographicVolumeNumber":"76","bibliographic_titles":[{"bibliographic_title":"四国医学雑誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Shikoku Acta Medica","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Recently, immune checkpoint inhibitors（ICI）have been approved for use in advanced gastric cancer（AGC）based on the positive results of ATTRACTION‐２ trial in Japan. There has been accumulating evidence that the development of immune-related adverse events（irAE）may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined ２９ patients with AGC who received nivolumab therapy in our departments. Among them, １５ patients（５２％）developed irAEs including ４ patients（１４％）for grade ３ irAEs ; liver dysfunction（n＝２）, type １ diabetes mellitus（n＝２） and adrenal insufficiency（n＝１）. The median overall survival was１２．０months in the irAE group and ３．２５ months in the non-irAE group（p＝０．１６４）, which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"徳島医学会","subitem_publisher_language":"ja"}]},"item_10001_source_id_9":{"attribute_name":"収録物ID","attribute_value_mlt":[{"subitem_source_identifier":"00373699","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AN00102041","subitem_source_identifier_type":"NCID"}]},"item_10001_version_type_20":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1715043197608":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"藤井, 祥平","creatorNameLang":"ja"},{"creatorName":"フジイ, ショウヘイ","creatorNameLang":"ja-Kana"},{"creatorName":"Fujii, Shohei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"中村, 文香","creatorNameLang":"ja"},{"creatorName":"ナカムラ, フミカ","creatorNameLang":"ja-Kana"},{"creatorName":"Nakamura, Fumika","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"佐藤, 康史","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"852","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岸, 和弘","creatorNameLang":"ja"},{"creatorName":"キシ, カズヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"Kishi, Kazuhiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"吉田, 守美子","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"518","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"三井, 康裕","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"781","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"藤野, 泰輝","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"710","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"北村, 晋志","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"359","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"岡本, 耕一","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"349","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"宮本, 弘志","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"175","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"六車, 直樹","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"1572","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"高山, 哲治","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"287","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2020-10-20"}],"displaytype":"detail","filename":"sam_76_3-4_173.pdf","filesize":[{"value":"1.26 MB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://tokushima-u.repo.nii.ac.jp/record/2008297/files/sam_76_3-4_173.pdf"},"version_id":"f02cf78b-6d0a-48fa-b419-14e1594d1210"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Immune-checkpoint inhibitors","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Gastric cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Immune-related adverse events","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nivolumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用（irAE）との関連性についての検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用（irAE）との関連性についての検討","subitem_title_language":"ja"}]},"item_type_id":"40001","owner":"7","path":["1713853295607","1716422749171"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-10-20"},"publish_date":"2020-10-20","publish_status":"0","recid":"2008297","relation_version_is_last":true,"title":["胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用（irAE）との関連性についての検討"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2024-11-22T06:50:15.916615+00:00"}